Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX [NASD]
Genomic Health Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own1.40% Shs Outstand32.17M Perf Week-6.00%
Market Cap971.86M Forward P/E419.58 EPS next Y0.07 Insider Trans-8.83% Shs Float31.43M Perf Month-2.71%
Income-24.60M PEG- EPS next Q-0.25 Inst Own94.50% Short Float8.03% Perf Quarter-6.87%
Sales275.70M P/S3.53 EPS this Y-85.70% Inst Trans0.08% Short Ratio19.02 Perf Half Y3.92%
Book/sh4.58 P/B6.60 EPS next Y111.30% ROA-13.70% Target Price31.90 Perf Year11.93%
Cash/sh3.22 P/C9.38 EPS next 5Y- ROE-17.20% 52W Range23.90 - 37.74 Perf YTD-5.51%
Dividend- P/FCF- EPS past 5Y-18.80% ROI-16.50% 52W High-19.95% Beta0.46
Dividend %- Quick Ratio3.90 Sales past 5Y13.00% Gross Margin82.30% 52W Low26.40% ATR1.18
Employees752 Current Ratio3.90 Sales Q/Q0.40% Oper. Margin-8.60% RSI (14)39.99 Volatility3.68% 3.82%
OptionableYes Debt/Eq0.00 EPS Q/Q33.30% Profit Margin-8.90% Rel Volume0.82 Prev Close29.66
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout- Avg Volume132.76K Price30.21
Recom2.70 SMA20-5.40% SMA50-4.82% SMA200-0.91% Volume108,333 Change1.85%
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Feb-09-11Downgrade Ladenburg Thalmann Buy → Neutral
Nov-16-10Initiated Canaccord Genuity Hold $19
Apr-21-10Initiated RBC Capital Mkts Sector Perform
Apr-14-10Initiated William Blair Mkt Perform
Jan-22-10Upgrade Piper Jaffray Neutral → Overweight
Jan-21-10Initiated Jefferies & Co Hold $18
Jan-08-10Initiated ThinkEquity Buy
Jun-11-09Upgrade Thomas Weisel Market Weight → Overweight $23
Oct-08-08Initiated Oppenheimer Perform
Sep-08-08Downgrade Canaccord Adams Buy → Hold $24 → $22
Aug-06-08Reiterated JMP Securities Mkt Outperform $32 → $35
Mar-20-15 09:02AM  Multiple Data Presentations Demonstrate Positive Direct Patient Impact of Oncotype DX® Breast Cancer Test Globally at noodls
08:00AM  Multiple Data Presentations Demonstrate Positive Direct Patient Impact of Oncotype DX® Breast Cancer Test Globally PR Newswire
Mar-19-15 01:04PM  GENOMIC HEALTH INC Financials
Mar-18-15 12:50PM  Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog
Mar-12-15 04:47PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report
Mar-10-15 12:43PM  Coverage initiated on Genomic Health by UBS
Feb-20-15 04:14PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-15 10:39PM  Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook at noodls
Feb-12-15 09:05AM  Genetic testing firm Invitae tops IPO targets, raises $102M at American City Business Journals
Feb-11-15 10:06AM  Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Feb-10-15 05:33PM  Genomic Health reports 4Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:06PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:02PM  Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook PR Newswire
07:07AM  Q4 2014 Genomic Health Inc Earnings Release - After Market Close CCBN
Feb-05-15 07:00AM  Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test PR Newswire
04:00AM  Inivata Limited Announces New Board Member Patrick Terry PR Newswire
Feb-03-15 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on Tuesday, February 10, 2015 PR Newswire
Feb-02-15 09:03AM  Should You Buy Genomic Health (GHDX) Ahead of Earnings? - Tale of the Tape Zacks
Jan-30-15 04:07PM  GENOMIC HEALTH INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Sta EDGAR Online
Jan-12-15 01:18AM  Genomic Health Plans Line of Liquid-Biopsy Tests for Cancer at The Wall Street Journal
Jan-09-15 09:49PM  Genetic testing firm Invitae seeks IPO of $86 million (Video) at American City Business Journals
Jan-05-15 08:00AM  Genomic Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-18-14 08:00AM  Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer PR Newswire
Dec-16-14 07:30AM  Genomic Health Test Could Reduce Overtreatment Of Breast Cancer at Forbes
Dec-12-14 08:30AM  Oncotype DX® DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer PR Newswire
Dec-11-14 02:40PM  Genomic Health's Liquid Biopsy Tests Positive in Twin Studies Zacks
Dec-10-14 08:00AM  Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test PR Newswire
Dec-09-14 09:00AM  Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests PR Newswire
Dec-04-14 01:40PM  Genomic Health's Oncotype DX: Cancer Testing Made Easier Zacks
Dec-03-14 09:21AM  Genomic Health (GHDX) Downgraded From Hold to Sell at TheStreet
08:00AM  Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations PR Newswire
Dec-02-14 08:00AM  2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12 PR Newswire
Nov-26-14 04:00PM  Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-19-14 08:00AM  Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively PR Newswire
Nov-12-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -9.37%
Nov-11-14 09:10AM  New Cancer Detection Technique Has Enormous Potential for Life Science Stocks at 24/7 Wall St.
Nov-10-14 04:08PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-08-14 07:07PM  10-Q for Genomic Health, Inc. Company Spotlight
Nov-06-14 05:12PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
01:50PM  Genomic Health Q3 Loss Narrower than Expected, Revenues Lag Zacks
Nov-04-14 06:31PM  Genomic Health beats 3Q profit forecasts AP
04:05PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S. Invasive Breast Cancer Business PR Newswire
09:17AM  Genomic Health (GHDX) Upgraded From Sell to Hold at TheStreet
08:00AM  Genomic Health to Present at the Credit Suisse Annual Healthcare Conference PR Newswire
07:07AM  Q3 2014 Genomic Health Inc Earnings Release - After Market Close CCBN
Oct-28-14 08:00AM  Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014 PR Newswire
Oct-15-14 05:52PM  Should Genomic Health (GHDX) Be in Your Portfolio Now? Zacks
Sep-29-14 08:00AM  Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients PR Newswire
Sep-26-14 08:00AM  Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) PR Newswire
Sep-25-14 02:00PM  Genomic Health Upbeat on Strong International Performance Zacks
Sep-24-14 08:00AM  New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre PR Newswire
Sep-22-14 02:20PM  Is Illumina (ILMN) Worth Adding to Your Portfolio? Zacks
Sep-15-14 02:00PM  Genomic Health Reveals Positive Oncotype DX Test Results Zacks
Sep-12-14 08:00AM  Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics PR Newswire
Sep-09-14 08:00AM  Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress PR Newswire
Aug-20-14 09:45AM  Flatley's Law: How One Company Is Creating Medicine's Genetic Revolution at Forbes
Aug-14-14 11:10AM  Genomic Health Raised to Buy on Better-than-Expected Q2 Zacks
Aug-11-14 08:20AM  Genomic Health Q2 Loss Narrower than Expected, Shares Up Zacks
Aug-08-14 04:36PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08:00AM  Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference PR Newswire
Aug-07-14 04:13PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress PR Newswire
07:07AM  Q2 2014 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
Aug-06-14 08:00AM  Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints PR Newswire
06:37AM  Is a Surprise Coming for Genomic Health (GHDX) This Earnings Season? Zacks
Jul-31-14 08:00AM  Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 PR Newswire
Jul-14-14 03:23PM  Is NanoString The Next Illumina In Cancer Diagnostics? at Seeking Alpha
11:00AM  3 Health Care Stocks Primed For Big Moves StreetAuthority Network
Jul-10-14 11:48AM  Show of support for Genomic Health optionMONSTER
Jul-03-14 01:30PM  Genomic Grows on Breast Cancer Test, Margin Pressure Continues Zacks
Jun-19-14 04:16PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jun-12-14 04:02PM  Genomic Health's Oncotype DX Redefines Breast Cancer Therapy Zacks
Jun-11-14 08:00AM  Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of Oncotype DX® in DCIS Breast Cancer PR Newswire
Jun-10-14 04:03PM  GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
03:00AM  Multiple studies presented at 2014 ASCO® annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test Business Wire
Jun-05-14 01:50PM  Genomic Health Up on Fresh Cancer Study Data Zacks
Jun-03-14 08:00AM  Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers PR Newswire
Jun-01-14 09:00AM  Multiple Studies Presented at ASCO® Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX® to Optimize Cancer Care PR Newswire
May-30-14 01:00PM  Genomic Health Posts Fresh Oncotype DX Data Zacks
May-29-14 08:00AM  Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out PR Newswire
May-23-14 08:00AM  Genomic Health to Present at Two Upcoming Investor Conferences PR Newswire
May-21-14 01:50PM  Genomic Health: Study Boosts Oncotype DX Again Zacks
May-20-14 05:02PM  Genomic Health announces data reinforcing robustness of Oncotype DX at theflyonthewall.com
04:57PM  Genomic Health Announces Data Reinforcing Robustness of Oncotype DX® Prostate Cancer Test at 2014 American Urological Association (AUA) Annual Meeting PR Newswire
May-19-14 02:20PM  Genomic Health Presents New Oncotype DX Data Zacks
May-16-14 04:03PM  Genomic Health says studies show test predicts prostate cancer aggressiveness at theflyonthewall.com
04:00PM  European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's Oncotype DX® Test Predicts Prostate Cancer Aggressiveness at Diagnosis PR Newswire
May-14-14 08:00AM  Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry PR Newswire
May-09-14 02:30PM  Q1 Loss Wider than Expected at Genomic Health Zacks
May-07-14 04:08PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
May-06-14 04:06PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces First Quarter 2014 Financial Results and Business Progress PR Newswire
07:07AM  Q1 2014 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
May-05-14 08:00AM  Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-02-14 08:13AM  Genomic Health reports positive results from Oncotype DX study theflyonthewall.com -5.59%
08:00AM  Oncotype DX® Changes Treatment Decisions in 45 Percent of Stage II Colon Cancer Patients PR Newswire
Apr-29-14 08:00AM  Genomic Health to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 6, 2014 PR Newswire
Apr-22-14 08:00AM  Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones PR Newswire
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEOMar 12Option Exercise18.893,00056,67037,939Mar 17 05:50 PM
Popovits Kimberly JPresident and CEOMar 12Sale31.913,00095,71734,939Mar 17 05:50 PM
Cole G BradleyCOOMar 10Option Exercise9.394,00037,56033,658Mar 12 04:05 PM
Cole G BradleyCOOMar 10Sale31.844,000127,37629,658Mar 12 04:05 PM
Popovits Kimberly JPresident and CEOFeb 12Option Exercise18.893,00056,67039,965Feb 17 07:12 PM
Popovits Kimberly JPresident and CEOFeb 12Sale29.863,00089,56636,965Feb 17 07:12 PM
Cole G BradleyCOOFeb 10Option Exercise9.394,00037,56025,645Feb 12 05:30 PM
Cole G BradleyCOOFeb 10Sale31.374,000125,46821,645Feb 12 05:30 PM
LIVINGSTON RANDALL SDirectorFeb 02Option Exercise10.731,00010,7307,149Feb 04 04:58 PM
LIVINGSTON RANDALL SDirectorFeb 02Sale31.931,00031,9316,149Feb 04 04:58 PM
Popovits Kimberly JPresident and CEOJan 12Option Exercise18.893,00056,67039,965Jan 14 04:34 PM
Popovits Kimberly JPresident and CEOJan 12Sale33.463,000100,38636,965Jan 14 04:34 PM
Popovits Kimberly JPresident and CEODec 11Option Exercise18.893,00056,67039,365Dec 15 04:13 PM
Popovits Kimberly JPresident and CEODec 11Sale32.993,00098,96736,965Dec 15 04:13 PM
Cole G BradleyCOODec 08Option Exercise9.394,33640,71525,981Dec 09 04:25 PM
Cole G BradleyCOODec 08Sale32.524,336141,00421,645Dec 09 04:25 PM
Popovits Kimberly JPresident and CEONov 12Option Exercise18.894,30081,22739,165Nov 14 07:07 PM
Popovits Kimberly JPresident and CEONov 12Sale34.824,300149,70936,965Nov 14 07:07 PM
Cole G BradleyCOONov 10Option Exercise9.394,00037,56026,891Nov 12 04:32 PM
Cole G BradleyCOONov 10Sale35.354,000141,38822,891Nov 12 04:32 PM
LIVINGSTON RANDALL SDirectorNov 03Option Exercise10.733,00032,1909,149Nov 05 05:01 PM
LIVINGSTON RANDALL SDirectorNov 03Sale36.243,000108,7196,149Nov 05 05:01 PM
Popovits Kimberly JPresident and CEOOct 13Option Exercise18.893,00056,67039,965Oct 15 04:22 PM
Popovits Kimberly JPresident and CEOOct 13Sale30.783,00092,32636,965Oct 15 04:22 PM
Cole G BradleyCOOOct 08Option Exercise9.394,00037,56026,891Oct 10 04:19 PM
Cole G BradleyCOOOct 08Sale28.774,000115,09822,891Oct 10 04:19 PM
Popovits Kimberly JPresident and CEOSep 11Option Exercise16.953,00050,84739,965Sep 15 04:16 PM
Popovits Kimberly JPresident and CEOSep 11Sale29.823,00089,44636,965Sep 15 04:16 PM
Shak StevenEVP of R&DAug 14Option Exercise2.886,34818,282318,646Aug 15 05:21 PM
Shak StevenEVP of R&DAug 14Sale27.496,348174,498312,298Aug 15 05:21 PM
Shak StevenEVP of R&DAug 13Option Exercise2.887,00020,160319,298Aug 15 05:21 PM
Shak StevenEVP of R&DAug 13Sale27.257,000190,726312,298Aug 15 05:21 PM
Popovits Kimberly JPresident and CEOAug 12Option Exercise9.393,00028,17039,965Aug 14 04:54 PM
Popovits Kimberly JPresident and CEOAug 12Sale26.073,00078,20136,965Aug 14 04:54 PM
Popovits Kimberly JPresident and CEOJul 14Option Exercise9.393,00028,17039,965Jul 16 04:17 PM
Popovits Kimberly JPresident and CEOJul 14Sale26.593,00079,77736,965Jul 16 04:17 PM
Cole G BradleyCOOJul 08Option Exercise2.882,3006,62425,191Jul 10 04:19 PM
Cole G BradleyCOOJul 08Sale27.052,30062,20922,891Jul 10 04:19 PM
Shak StevenEVP of R&DJul 01Option Exercise2.887,00020,160319,298Jul 03 06:04 PM
Shak StevenEVP of R&DJul 01Sale27.007,000188,970312,298Jul 03 06:04 PM
Popovits Kimberly JPresident and CEOJun 12Option Exercise9.393,00028,17039,965Jun 16 06:03 PM
Shak StevenEVP of R&DJun 12Option Exercise2.887,00020,160319,298Jun 16 06:08 PM
Shak StevenEVP of R&DJun 12Sale26.737,000187,107312,298Jun 16 06:08 PM
Popovits Kimberly JPresident and CEOJun 12Sale26.103,00078,29536,965Jun 16 06:03 PM
Schorno Dean LCFOJun 10Option Exercise18.044,00072,14028,524Jun 13 08:07 PM
Schorno Dean LCFOJun 10Sale27.624,000110,48724,524Jun 13 08:07 PM
Cole G BradleyCOOJun 09Option Exercise2.882,3376,73125,228Jun 11 05:48 PM
Cole G BradleyCOOJun 09Sale27.292,33763,76722,891Jun 11 05:48 PM
Popovits Kimberly JPresident and CEOMay 12Option Exercise9.393,00028,17039,255May 14 04:04 PM
Popovits Kimberly JPresident and CEOMay 12Sale26.543,00079,61736,255May 14 04:04 PM
Schorno Dean LCFOMay 09Option Exercise18.044,00072,14027,814May 13 04:05 PM
Schorno Dean LCFOMay 09Sale25.094,000100,35923,814May 13 04:05 PM
Shak StevenEVP of R&DApr 14Option Exercise2.887,00020,160318,547Apr 16 04:19 PM
Shak StevenEVP of R&DApr 14Sale26.257,000183,734311,588Apr 16 04:19 PM
Cole G BradleyCOOApr 08Option Exercise2.883,0008,64025,226Apr 10 04:20 PM
Cole G BradleyCOOApr 08Sale27.003,00081,00022,226Apr 10 04:20 PM